BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee

Sarah A Holstein, Hervé Avet-Loiseau, Theresa Hahn, Christine M. Ho, Jens G. Lohr, Nikhil C. Munshi, Bruno Paiva, Marcelo C. Pasquini, Joseph D. Tario, Saad Z. Usmani, Paul K. Wallace, Katja Weisel, Philip L. McCarthy

Research output: Contribution to journalReview article

7 Scopus citations

Abstract

The Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 1, 2016 at the American Society of Hematology meeting to discuss the emerging data and technologies for minimal residual disease assessment and immune profiling in myeloma. Particular emphasis was placed on developing strategies to incorporate these techniques into clinical trial design. This document reviews the literature, summarizes the topics discussed in the workshop, and provides recommendations for integration of these techniques into future clinical trial design.

Original languageEnglish (US)
Pages (from-to)641-648
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume24
Issue number4
DOIs
StatePublished - Apr 2018

    Fingerprint

Keywords

  • Immune profiling
  • Minimal residual disease
  • Multiple myeloma, autologous stem cell transplant

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Holstein, S. A., Avet-Loiseau, H., Hahn, T., Ho, C. M., Lohr, J. G., Munshi, N. C., Paiva, B., Pasquini, M. C., Tario, J. D., Usmani, S. Z., Wallace, P. K., Weisel, K., & McCarthy, P. L. (2018). BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee. Biology of Blood and Marrow Transplantation, 24(4), 641-648. https://doi.org/10.1016/j.bbmt.2017.12.774